In this week’s View, Dr. Eagle explores the long-term mortality of patients with Ebstein Anomaly. He then discusses a study that looks at the modifiability of cardiovascular risk associated with chronic kidney disease in patients with type 2 diabetes treated with finerenone. Finally, Dr. Eagle looks at the effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. 

 Subscribe to Eagle’s Eye View